|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 April 2001, Vol. 97, No. 7, pp. 2105-2114
NEOPLASIA
Synergistic induction of apoptosis in human leukemia cells (U937)
exposed to bryostatin 1 and the proteasome inhibitor lactacystin
involves dysregulation of the PKC/MAPK cascade
Julie A. Vrana and
Steven Grant
From the Departments of Medicine, Microbiology,
Pharmacology, and Biochemistry, Medical College of Virginia, Virginia
Commonwealth University, Richmond, VA.
Cotreatment with a minimally toxic concentration of the protein
kinase C (PKC) activator (and down-regulator) bryostatin 1 (BRY)
induced a marked increase in mitochondrial dysfunction and apoptosis in
U937 monocytic leukemia cells exposed to the proteasome inhibitor
lactacystin (LC). This effect was blocked by cycloheximide, but not by
 -amanitin or actinomycin D. Qualitatively similar interactions were
observed with other PKC activators (eg, phorbol 12-myristate 13-acetate
and mezerein), but not phospholipase C, which does not down-regulate
the enzyme. These events were examined in relationship to functional
alterations in stress (eg, SAPK, JNK) and survival (eg, MAPK, ERK)
signaling pathways. The observations that LC/BRY treatment failed to
trigger JNK activation and that cell death was unaffected by a
dominant-interfering form of c-JUN (TAM67) or by pretreatment with
either curcumin or the p38/RK inhibitor, SB203580, suggested that the
SAPK pathway was not involved in potentiation of apoptosis. In marked
contrast, perturbations in the PKC/Raf/MAPK pathway played an integral
role in LC/BRY-mediated cell death based on evidence that pretreatment
of cells with bisindolylmaleimide I, a selective PKC inhibitor, or
geldanamycin, a benzoquinone ansamycin, which destabilizes and depletes
Raf-1, markedly suppressed apoptosis. Furthermore, ERK phosphorylation
was substantially prolonged in LC/BRY-treated cells compared to those
exposed to BRY alone, and pretreatment with the highly specific MEK
inhibitors, PD98059, U0126, and SL327, opposed ERK activation while
protecting cells from LC/BRY-induced lethality. Together, these
findings suggest a role for activation and/or dysregulation of the
PKC/MAPK cascade in modulation of leukemic cell apoptosis following
exposure to the proteasome inhibitor LC.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Li, W. Wojciechowski, C. Dell'Agnola, N. E. Lopez, and I. Espinoza-Delgado
IFN-{gamma} and T-bet Expression in Human Dendritic Cells from Normal Donors and Cancer Patients Is Controlled through Mechanisms Involving ERK-1/2-Dependent and IL-12-Independent Pathways
J. Immunol.,
September 15, 2006;
177(6):
3554 - 3563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Kuzirian, H. T. Epstein, C. J. Gagliardi, T. J. Nelson, M. Sakakibara, C. Taylor, A. B. Scioletti, and D. L. Alkon
Bryostatin Enhancement of Memory in Hermissenda
Biol. Bull.,
June 1, 2006;
210(3):
201 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wojciechowski, H. Li, S. Marshall, C. Dell'Agnola, and I. Espinoza-Delgado
Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms
J. Immunol.,
June 15, 2005;
174(12):
7859 - 7868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Peiretti, M. Canault, D. Bernot, B. Bonardo, P. Deprez-Beauclair, I. Juhan-Vague, and G. Nalbone
Proteasome inhibition activates the transport and the ectodomain shedding of TNF-{alpha} receptors in human endothelial cells
J. Cell Sci.,
March 1, 2005;
118(5):
1061 - 1070.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Fernandez, A. M. Ramos, P. Sancho, D. Amran, E. de Blas, and P. Aller
12-O-Tetradecanoylphorbol-13-acetate May Both Potentiate and Decrease the Generation of Apoptosis by the Antileukemic Agent Arsenic Trioxide in Human Promonocytic Cells: REGULATION BY EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASES AND GLUTATHIONE
J. Biol. Chem.,
January 30, 2004;
279(5):
3877 - 3884.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Battle and D. A. Frank
STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1
Blood,
October 15, 2003;
102(8):
3016 - 3024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hetman, S.-L. Hsuan, A. Habas, M. J. Higgins, and Z. Xia
ERK1/2 Antagonizes Glycogen Synthase Kinase-3beta -induced Apoptosis in Cortical Neurons
J. Biol. Chem.,
December 13, 2002;
277(51):
49577 - 49584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kanzaki, Y. Takebayashi, X.-Q. Ren, H. Miyashita, S. Mori, S.-i. Akiyama, and Y. Pommier
Overcoming Multidrug Drug Resistance in P-Glycoprotein/MDR1-overexpressing Cell Lines by Ecteinascidin 743
Mol. Cancer Ther.,
December 1, 2002;
1(14):
1327 - 1334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Z. Orlowski, G. W. Small, and Y. Y. Shi
Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis
J. Biol. Chem.,
July 26, 2002;
277(31):
27864 - 27871.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
